Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma-Reference-Cited by-同舟云学术

Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma

Published:2020-11-25 Issue:3 Volume:62 Page:722-726
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Papadakis Vassilios¹,Efstathopoulou Maria²,Angelopoulou Maria K.²,Tsourouflis Gerassimos³,Prassopoulos Vassilios⁴,Rondogianni Phivi⁵,Kourtesis Antonios⁶,Polychronopoulou Sophia¹,Pangalis Gerassimos A.²⁷,Vassilakopoulos Theodoros P.²

Affiliation:

1. Department of Pediatric Hematology- Oncology, Agia Sofia Children's Hospital, Athens, Greece

2. Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece

3. Second Department of Surgery, Propedeutic, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece

4. Department of Nuclear Medicine, HYGEIA Hospital, Athens, Greece

5. Department of Nuclear Medicine and PET/CT, Evangelismos General Hospital, Athens, Greece

6. Department of Pediatric Cardiac Surgery, Agia Sofia Children's Hospital, Athens, Greece

7. Department of Hematology, Athens Medical Center, Athens, Greece

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1842404

Reference15 articles.

1. Treatment of Hodgkin Lymphoma: A 50-Year Perspective

2. Advanced and Relapsed/Refractory Hodgkin Lymphoma: What Has Been Achieved During the Last 50 Years

3. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

4. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

5. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomodulatory Treatment Regimen, MEPED, Rescues Relapsed and Refractory Classic Hodgkin’s Disease;Frontiers in Pharmacology;2021-06-18